- Conditions
- Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
- Interventions
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 784
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 511 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 1,115
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Salmeterol 50mcg/ Fluticasone Propionate 500mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 6,228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 190
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 152 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- linagliptin, glimepiride, linagliptin placebo, glimepiride placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 6,103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 177
- States / cities
- Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 139 more
- Conditions
- Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
- Interventions
- nab-sirolimus
- Drug
- Lead sponsor
- Aadi Bioscience, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 159
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more
- Conditions
- Alzheimer's Disease
- Interventions
- Aducanumab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,027 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 130
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Interventions
- aflibercept, High-dose aflibercept
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Encino, California + 42 more
- Conditions
- Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Distal Bile Duct Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Gallbladder Cancer AJCC v8, Stage IVB Gallbladder Cancer AJCC v8, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 692
- States / cities
- Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 448 more
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Interventions
- Surovatamig
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Fullerton, California • Plantation, Florida + 3 more
- Conditions
- Breast Cancer
- Interventions
- Placebo, GLSI-100
- Biological
- Lead sponsor
- Greenwich LifeSciences, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 2,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 51
- States / cities
- Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 56
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
- Conditions
- Intermittent Exotropia
- Interventions
- Vision Therapy
- Other
- Lead sponsor
- Southern California College of Optometry at Marshall B. Ketchum University
- Other
- Eligibility
- 8 Years to 16 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Fullerton, California • Stanford, California + 3 more
- Conditions
- Obesity, Overweight, Chronic Low Back Pain (CLBP)
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 25
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 22 more
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Molnupiravir, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,441 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 53 more
- Conditions
- Multiple Sclerosis
- Interventions
- glatiramer acetate, Warm compress prior to injection of glatiramer acetate
- Drug · Procedure
- Lead sponsor
- Teva Neuroscience, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 6
- States / cities
- Fullerton, California • Miami, Florida • Springfield, Massachusetts + 3 more
- Conditions
- Walking Impairment, Multiple Sclerosis
- Interventions
- ADS-5102, 137 mg, ADS-5102, 274 mg, Placebo
- Drug · Other
- Lead sponsor
- Adamas Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 78
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 73 more
- Conditions
- Cognitive Impairment, Malignant Neoplasm
- Interventions
- Ibuprofen, Placebo, Questionnaire Administration
- Drug · Other
- Lead sponsor
- University of Rochester NCORP Research Base
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 169
- States / cities
- Burbank, California • Lewes, Delaware • Newark, Delaware + 99 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- natalizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 11
- States / cities
- Fullerton, California • Aurora, Colorado • Des Moines, Iowa + 8 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Abemaciclib, Fulvestrant, Standard Chemotherapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 55
- States / cities
- Avondale, Arizona • Phoenix, Arizona • Yuma, Arizona + 51 more
- Conditions
- Breast Neoplasms
- Interventions
- Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 46
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Fullerton, California + 38 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 78
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 68 more
- Conditions
- Respiratory Monitoring
- Interventions
- Makani Science Respiratory Monitoring System
- Device
- Lead sponsor
- Makani Science
- Industry
- Eligibility
- 22 Years to 99 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 1,014 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 132
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
- Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1021
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 643 more
- Conditions
- Non-Small-Cell Lung Carcinoma, Neoplasm Recurrence, Local
- Interventions
- Avastin (bevacizumab), Tarceva (erlotinib HCl)
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 48
- States / cities
- Bakersfield, California • Concord, California • Fullerton, California + 40 more